Semler Scientific Inc. (SMLR)
Market Cap | 590.42M |
Revenue (ttm) | 35.68M |
Net Income (ttm) | 11.45M |
Shares Out | 6.58M |
EPS (ttm) | 1.44 |
PE Ratio | 61.80 |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 15 |
Last Price | $88.68 |
Previous Close | $82.00 |
Change ($) | 6.68 |
Change (%) | 8.14% |
Day's Open | 82.15 |
Day's Range | 82.15 - 89.73 |
Day's Volume | 8,083 |
52-Week Range | 30 - 95 |
SANTA CLARA, Calif., Jan. 7, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of he...
The pandemic blip seems all but a distant memory for the company even if not all of the risk has cleared. The company just keeps growing and producing awe-inspiring margins, it doesn't happen ...
Top Ranked Momentum Stocks to Buy for November 17th
Top Ranked Momentum Stocks to Buy for November 12th
SANTA CLARA, Calif., Nov. 12, 2020 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of h...
Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q3 2020 Results - Earnings Call Transcript
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 258.82% and 24.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Discover how these three companies could change the face of healthcare.
While the company has experienced headwinds from the pandemic, growth is already returning.
FMS vs. SMLR: Which Stock Is the Better Value Option?
FMS vs. SMLR: Which Stock Is the Better Value Option?
No matter what the month, stay the course.
SAN JOSE, Calif., Aug. 17, 2020 /PRNewswire/ -- Semler Scientific, Inc.
FMS vs. SMLR: Which Stock Is the Better Value Option?
Semler Scientific's (SMLR) CEO Doug Murphy-Chutorian on Q2 2020 Results - Earnings Call Transcript
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 116.67% and -15.48%, respectively, for the quarter ended June 2020.
All three offer innovative technology that meets major healthcare needs.
3 Potentially Undervalued Small-Cap Ideas
There’s a lot to like about investing in the healthcare sector, so get to know three stocks that make great investments right now.
Semler Scientific (SMLR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
I'm putting real money behind these hidden healthcare winners.
Semler Scientific is a high growth company with annual sales increasing at a CAGR of 37% since 2015.
The company has simplified the testing of PAD, which is a marker for increased risk of stroke and cardiovascular disease.
Semler Scientific: High-Quality Medical Stock With Cash Flow Growth And Zero Debt
Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q1 2020 Results - Earnings Call Transcript
It's time to get greedy with these beaten-down businesses.
Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q4 2019 Results - Earnings Call Transcript
These three companies are all growing like gangbusters and have already reached profitability.
We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.
About SMLR
Semler Scientific develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans... [Read more...]
Industry Medical Devices | IPO Date Feb 21, 2014 |
CEO Douglas Murphy-Chutorian | Employees 67 |
Stock Exchange OTCMKTS | Ticker Symbol SMLR |
Financial Performance
In 2019, SMLR's revenue was $32.77 million, an increase of 52.47% compared to the previous year's $21.49 million. Earnings were $15.08 million, an increase of 200.84%.
Analyst Forecasts
The average 12-month stock price forecast for SMLR is 94.67, which is an increase of 6.76% from the latest price.